Skip Nav | Home | Mobile | Editorial Guidelines | Mission Statement | About Us | Contact | Help | Security | Support Us

World

Hidden Article

This posting has been hidden because it breaches the Indymedia UK (IMC UK) Editorial Guidelines.

IMC UK is an interactive site offering inclusive participation. All postings to the open publishing newswire are the responsibility of the individual authors and not of IMC UK. Although IMC UK volunteers attempt to ensure accuracy of the newswire, they take no responsibility legal or otherwise for the contents of the open publishing site. Mention of external web sites or services is for information purposes only and constitutes neither an endorsement nor a recommendation.

New Report Predicts that Novartis' Diovan, Glivec/Gleevec and Zelmac/Zelnorm wil

Mr Roger K. Olsson | 11.08.2007 21:41 | Analysis | Other Press | Technology | London | World

Giuen Wellness Merchant Press





Aug. 3, 2007 (M2 Communications Ltd. delivered by Newstex) --

Research and Markets ( http://www.researchandmarkets.com/reports/c64757) has announced the addition of Novartis: Performance, Products, Pipeline and Potential to their offering

Pharmaceutical company intelligence reports provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of itscccccccclatest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.

Following the merger of Ciba and Sandoz, the spin-off of the Agribusiness sector and the sale of the remaining activities of the Industry division, Novartis has become a leading company in the life sciences field and has operations in approximately 140 countries worldwide. Novartis is currently organised into the four divisions of Pharmaceuticals, Consumer Health, Sandoz and Vaccines & Diagnostics, created following the acquisition of Chiron Corporation. Within Pharmaceuticals, the company's current growth drivers include Diovan (valsartan), Glivec/Gleevec (imatinib), Femara (letrozole) and Zometa (zoledronate).

Novartis' current pharma growth drivers together account for approximately 38 per cent of total pharma sales, and we predict that Diovan, Glivec/Gleevec and Zelmac/Zelnorm will continue to demonstrate substantial sales growth within the medium term. In addition, the recent launch and approval of a selection of products which include Exjade (deferasirox), Prexige (lumiracoxib), Xolair (omalizumab), Exforge (valsartan+amlodipine), Lucentis (ranibizumab) and Tekturna (aliskiren), should offset the decline in sales of a number of Novartis' strategic products. However, this confidence is tempered by the recent setbacks to the fortunes of Zelnorm/Zelmac (tegaserod) and Tekturna.

As a research-intensive company which has benefited from the Chiron acquisition, Novartis has a strong pharma pipeline with a total of 138 compounds under development. Of particular note are: Galvus (vildagliptin), filed for Type II diabetes in the US and the EU; and fingolimod under Phase III development for multiple sclerosis. However, Novartis still faces some hurdles since the approvable letter for Galvus has allowed Merck's Januvia a head start in the important US market.

Novartis' major company strategy is based on innovation and achieving a leading position in the healthcare sector. To this end, in 2005, the Pharmaceuticals division further expanded its research operations and this process continued in 2006. Pharmaceuticals remains Novartis' largest and most profitable business, with the Cardiovascular and Oncology franchises continuing as the leading therapeutic areas. Chiron's pharmaceutical operations are being integrated into the Pharmaceuticals division.

In the light of government cost containment measures, Novartis intends to develop new growth platforms such as vaccines (which will reduce costs through disease prevention) and expand its generic business (so capitalising on governments' promotion of generics).

This new strategic analysis report Novartis: Performance, Products, Pipeline and Potential, provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. The report is updated on a quarterly basis. Buyers of the web edition receive quarterly reports for a year. Buyers of the print/pdf editions receive the latest version. All formats are the same price.

EXECUTIVE SUMMARY

A detailed and comprehensive overview of current financial position, company strategy, product and pipeline analysis.

THERAPEUTIC AREA FOCUS

Key product analysis and forecasting

Cardiovascular and Metabolism

Diovan/Co-Diovan (valsartan)

Exforge (amlodipine+valsartan)

Lescol (fluvastatin)

Lotrel (amlodipine+benazepril)

Tekturna (aliskiren)

Oncology/Haematology

Exjade (deferasirox)

Femara (letrozole)

Glivec/Gleevec (imatinib)

Sandostatin (octreotide)

Zometa/Aclasta (zoledronic acid)

Neuroscience

Comtan (entacapone)

Exelon (rivastigmine)

Ritalin/Focalin (methylphenidate)

Stalevo (entacapone)

Trileptal (oxcarbazepine)

Arthritis/Bone

Miacalcic/Miacalcin (synthetic salmon calcitonin)

Prexige (lumiracoxib)

Voltaren/Cataflam (diclofenac sodium)

Gastrointestinal

Zelnorm/Zelmac (tegaserod)

Respiratory/Dermatology

Elidel (pimecrolimus)

Foradil (formoterol fumarate)

Lamisil (terbinafine)

Xolair (omalizumab)

Transplantation/Immunology

Certican (everolimus)

Sandimmun/Neoral (ciclosporin)

Infectious Diseases

Famvir/Denavir (famciclovir)

Sebivo/Tyzeka (telbivudine)

Ophthalmics

Lucentis (ranibizumab)

Visudyne (verteporfin)

OPERATIONAL DATA

A wealth of background and detail

A full 5-year financial performance assessment

Key corporate events

Key agreements

Infrastructure

Subsidiaries

For more information visit  http://www.researchandmarkets.com/reports/c64757

Source: Espicom Business Intelligence

(Comments on this story may be sent to  tww.feedback@m2.com)


Newstex ID: MCOM-0001-18828037

Delivered by Newstex LLC
via theFinancials.com

Giuen Media
Advertising Agency
Sales and Promotion
 http://giuen.wordpress.com


Mr Roger K. Olsson
- e-mail: rogerkolsson@yahoo.co.uk
- Homepage: http://www.adbrite.com/mb/commerce/purchase_form.php?opid=377909&afsid=1

Publish

Publish your news

Do you need help with publishing?

/regional publish include --> /regional search include -->

World Topics

Afghanistan
Analysis
Animal Liberation
Anti-Nuclear
Anti-militarism
Anti-racism
Bio-technology
Climate Chaos
Culture
Ecology
Education
Energy Crisis
Fracking
Free Spaces
Gender
Globalisation
Health
History
Indymedia
Iraq
Migration
Ocean Defence
Other Press
Palestine
Policing
Public sector cuts
Repression
Social Struggles
Technology
Terror War
Workers' Movements
Zapatista

Kollektives

Birmingham
Cambridge
Liverpool
London
Oxford
Sheffield
South Coast
Wales
World

Other UK IMCs
Bristol/South West
London
Northern Indymedia
Scotland

Server Appeal Radio Page Video Page Indymedia Cinema Offline Newsheet

secure Encrypted Page

You are viewing this page using an encrypted connection. If you bookmark this page or send its address in an email you might want to use the un-encrypted address of this page.

If you recieved a warning about an untrusted root certificate please install the CAcert root certificate, for more information see the security page.

IMCs


www.indymedia.org

Projects
print
radio
satellite tv
video

Africa

Europe
antwerpen
armenia
athens
austria
barcelona
belarus
belgium
belgrade
brussels
bulgaria
calabria
croatia
cyprus
emilia-romagna
estrecho / madiaq
galiza
germany
grenoble
hungary
ireland
istanbul
italy
la plana
liege
liguria
lille
linksunten
lombardia
madrid
malta
marseille
nantes
napoli
netherlands
northern england
nottingham imc
paris/île-de-france
patras
piemonte
poland
portugal
roma
romania
russia
sardegna
scotland
sverige
switzerland
torun
toscana
ukraine
united kingdom
valencia

Latin America
argentina
bolivia
chiapas
chile
chile sur
cmi brasil
cmi sucre
colombia
ecuador
mexico
peru
puerto rico
qollasuyu
rosario
santiago
tijuana
uruguay
valparaiso
venezuela

Oceania
aotearoa
brisbane
burma
darwin
jakarta
manila
melbourne
perth
qc
sydney

South Asia
india


United States
arizona
arkansas
asheville
atlanta
Austin
binghamton
boston
buffalo
chicago
cleveland
colorado
columbus
dc
hawaii
houston
hudson mohawk
kansas city
la
madison
maine
miami
michigan
milwaukee
minneapolis/st. paul
new hampshire
new jersey
new mexico
new orleans
north carolina
north texas
nyc
oklahoma
philadelphia
pittsburgh
portland
richmond
rochester
rogue valley
saint louis
san diego
san francisco
san francisco bay area
santa barbara
santa cruz, ca
sarasota
seattle
tampa bay
united states
urbana-champaign
vermont
western mass
worcester

West Asia
Armenia
Beirut
Israel
Palestine

Topics
biotech

Process
fbi/legal updates
mailing lists
process & imc docs
tech